Figure 1 (Tecentriq 01)
Tecentriq Injection, Solution
Product Images NDC 50242-918
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tecentriq (NDC 50242-918). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Tecentriq 02)
This text seems to describe a graph showing the probability of survival after chemotherapy treatment using TECENTRIO and standard chemotherapy. The x-axis denotes the timeline in months, and the y-axis denotes the probability of survival. There are two lines plotted on the graph. The first line shows the probability of survival for patients treated with TECENTRIO, while the second line shows the probability of survival for patients treated with standard chemotherapy. However, without context or additional information, it is difficult to interpret the graph further.*
Figure 3 (Tecentriq 03)
Figure 4 (Tecentriq 04)
Figure 5 (Tecentriq 05)
Figure 6 (Tecentriq 06)
The text describes a chart or graph indicating the Overall Survival percentage over time in months, with comparative treatments shown for TECENTRIQ with Carboplatin and Etoposide, and Placebo with Carboplatin and Etoposide. The horizontal axis shows the Risk Time in months, and the vertical axis shows the Overall Survival percentage. There are multiple values over time for both TECENTRIQ and Placebo, with the highest overall survival.*
Figure 7 (Tecentriq 07)
This appears to be a chart displaying data related to the effectiveness of two different treatments on a group of patients over the course of several months. The treatments are listed as "TECENTRIQ+ bovecizumab" and "Sorafond". The chart shows the number of patients who remained under the treatment at each point in time (measured in months) and how many patients dropped out or experienced negative outcomes (indicated by the label "NE").*
Figure 8 (Tecentriq 08)
The given text is related to two drug combinations TECENTRIQ cobimetit vemurafents and cobmetinbsvemurlend. It also includes a graph displaying the probability of progression-free survival against time (in months). The table shows the number of patients remaining at risk for each of the given treatments. The description of the drugs' properties, usage or efficacy is not available, in the given text.*
Principal Display Panel (20 mL Vial Carton)
This is a product label for the medication Tecentriq® (atezolizumab). It is administered through injection and is meant for intravenous infusion after dilution. It comes in single-dose vials with no preservative. Any unused portion of the medication should be discarded. Pharmacists should dispense the accompanying medication guide to patients. The label also contains the NDC number, which is 50242-917-01, and a code number. The name of the manufacturer, Genentech, is also mentioned. Therefore, this text provides important information about the medication and its administration.*
Principal Display Panel (14 mL Vial Carton)
This is a prescription drug called Tecentriq® with the active ingredient atezolizumab. It is administered through an injection for intravenous infusion after dilution and comes in a single-dose vial. The unused portion should be discarded, and there is no preservative. The accompanying medication guide must be dispensed to every patient by the pharmacist. The drug is manufactured by Genentech and has the NDC code 50242-918-01.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
